1
|
Jia W, Han Y, Mao X, Xu W, Zhang Y. Nanotechnology strategies for hepatocellular carcinoma diagnosis and treatment. RSC Adv 2022; 12:31068-31082. [PMID: 36349046 PMCID: PMC9621307 DOI: 10.1039/d2ra05127c] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Accepted: 10/20/2022] [Indexed: 10/10/2023] Open
Abstract
Hepatocellular carcinoma (HCC) is a common malignancy threatening human health, and existing diagnostic and therapeutic techniques are facing great challenges. In the last decade or so, nanotechnology has been developed and improved for tumor diagnosis and treatment. For example, nano-intravenous injections have been approved for malignant perivascular epithelioid cell tumors. This article provides a comprehensive review of the applications of nanotechnology in HCC in recent years: (I) in radiological imaging, magnetic resonance imaging (MRI), fluorescence imaging (FMI) and multimodality imaging. (II) For diagnostic applications in HCC serum markers. (III) As embolic agents in transarterial chemoembolization (TACE) or directly as therapeutic drugs. (IV) For application in photothermal therapy and photodynamic therapy. (V) As carriers of chemotherapeutic drugs, targeted drugs, and natural plant drugs. (VI) For application in gene and immunotherapy. Compared with the traditional methods for diagnosis and treatment of HCC, nanoparticles have high sensitivity, reduce drug toxicity and have a long duration of action, and can also be combined with photothermal and photodynamic multimodal combination therapy. These summaries provide insights for the further development of nanotechnology applications in HCC.
Collapse
Affiliation(s)
- WeiLu Jia
- Medical School, Southeast University Nanjing 210009 China
| | - YingHui Han
- Outpatient Department, The Second Affiliated Hospital of Nanjing Medical University Nanjing 210009 China
| | - XinYu Mao
- Hepatopancreatobiliary Center, The Second Affiliated Hospital of Nanjing Medical University Nanjing 210009 China
| | - WenJing Xu
- Medical School, Southeast University Nanjing 210009 China
| | - YeWei Zhang
- Hepatopancreatobiliary Center, The Second Affiliated Hospital of Nanjing Medical University Nanjing 210009 China
| |
Collapse
|
2
|
Szczęch M, Karabasz A, Łopuszyńska N, Bzowska M, Węglarz WP, Warszyński P, Szczepanowicz K. Gadolinium labeled polyelectrolyte nanocarriers for theranostic application. Colloids Surf B Biointerfaces 2019; 183:110396. [PMID: 31394424 DOI: 10.1016/j.colsurfb.2019.110396] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Revised: 07/01/2019] [Accepted: 07/23/2019] [Indexed: 12/24/2022]
Abstract
Here, we designed a novel Gadolinium (Gd) labeled drug-loaded polyelectrolyte nanocarriers for theranostics. The nanocarriers were formed via layer-by-layer technique with biodegradable polyelectrolytes: PLL (Poly-L-lysine), PLL-Gd (Gadolinium-labeled Poly-L-lysine) and PGA (Poly-L-glutamic acid). Anticancer drug (Paclitaxel) was encapsulated in the formed nanocarriers. The average size of synthesized nanocarriers was around 150 nm. The empty gadolinium labeled nanocarriers did not show any deleterious effects on tested cells (CT26-CEA, B16F10, 4T1 and PBMC), whereas encapsulated paclitaxel retained its cytotoxic/cytostatic activity. Using T2 and T1 NMR relaxation measurements with 9.4 T preclinical MRI scanner, we demonstrated that gadolinium labeled nanocarriers can be detected due to a locally altered contrast in the MR image. Thus, they may become a promising platform for future theranostic applications.
Collapse
Affiliation(s)
- Marta Szczęch
- Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Krakow, Poland
| | - Alicja Karabasz
- Faculty of Biochemistry, Biophysics, and Biotechnology, Jagiellonian University, Krakow, Poland
| | - Natalia Łopuszyńska
- Henryk Niewodniczański Institute of Nuclear Physics, Polish Academy of Sciences, Krakow, Poland
| | - Monika Bzowska
- Faculty of Biochemistry, Biophysics, and Biotechnology, Jagiellonian University, Krakow, Poland
| | - Władysław P Węglarz
- Henryk Niewodniczański Institute of Nuclear Physics, Polish Academy of Sciences, Krakow, Poland
| | - Piotr Warszyński
- Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Krakow, Poland
| | - Krzysztof Szczepanowicz
- Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Krakow, Poland.
| |
Collapse
|
3
|
Narmani A, Farhood B, Haghi-Aminjan H, Mortezazadeh T, Aliasgharzadeh A, Mohseni M, Najafi M, Abbasi H. Gadolinium nanoparticles as diagnostic and therapeutic agents: Their delivery systems in magnetic resonance imaging and neutron capture therapy. J Drug Deliv Sci Technol 2018. [DOI: 10.1016/j.jddst.2018.01.011] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
4
|
Lakkireddy HR, Bazile D. Building the design, translation and development principles of polymeric nanomedicines using the case of clinically advanced poly(lactide(glycolide))-poly(ethylene glycol) nanotechnology as a model: An industrial viewpoint. Adv Drug Deliv Rev 2016; 107:289-332. [PMID: 27593265 DOI: 10.1016/j.addr.2016.08.012] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Revised: 08/19/2016] [Accepted: 08/27/2016] [Indexed: 12/16/2022]
Abstract
The design of the first polymeric nanoparticles could be traced back to the 1970s, and has thereafter received considerable attention, as evidenced by the significant increase of the number of articles and patents in this area. This review article is an attempt to take advantage of the existing literature on the clinically tested and commercialized biodegradable PLA(G)A-PEG nanotechnology as a model to propose quality building and outline translation and development principles for polymeric nano-medicines. We built such an approach from various building blocks including material design, nano-assembly - i.e. physicochemistry of drug/nano-object association in the pharmaceutical process, and release in relevant biological environment - characterization and identification of the quality attributes related to the biopharmaceutical properties. More specifically, as envisaged in a translational approach, the reported data on PLA(G)A-PEG nanotechnology have been structured into packages to evidence the links between the structure, physicochemical properties, and the in vitro and in vivo performances of the nanoparticles. The integration of these bodies of knowledge to build the CMC (Chemistry Manufacturing and Controls) quality management strategy and finally support the translation to proof of concept in human, and anticipation of the industrialization takes into account the specific requirements and biopharmaceutical features attached to the administration route. From this approach, some gaps are identified for the industrial development of such nanotechnology-based products, and the expected improvements are discussed. The viewpoint provided in this article is expected to shed light on design, translation and pharmaceutical development to realize their full potential for future clinical applications.
Collapse
|
5
|
Yang CT, Padmanabhan P, Gulyás BZ. Gadolinium(iii) based nanoparticles for T1-weighted magnetic resonance imaging probes. RSC Adv 2016. [DOI: 10.1039/c6ra07782j] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
This review summarized the recent progress on Gd(iii)-based nanoparticles asT1-weighted MRI contrast agents and multimodal contrast agents.
Collapse
Affiliation(s)
- Chang-Tong Yang
- Lee Kong Chian School of Medicine
- Nanyang Technological University
- Singapore 636921
| | | | - Balázs Z. Gulyás
- Lee Kong Chian School of Medicine
- Nanyang Technological University
- Singapore 636921
| |
Collapse
|
6
|
Nottelet B, Darcos V, Coudane J. Aliphatic polyesters for medical imaging and theranostic applications. Eur J Pharm Biopharm 2015; 97:350-70. [DOI: 10.1016/j.ejpb.2015.06.023] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2015] [Revised: 06/12/2015] [Accepted: 06/13/2015] [Indexed: 01/04/2023]
|
7
|
Wang H, Thorling CA, Liang X, Bridle KR, Grice JE, Zhu Y, Crawford DHG, Xu ZP, Liu X, Roberts MS. Diagnostic imaging and therapeutic application of nanoparticles targeting the liver. J Mater Chem B 2015; 3:939-958. [PMID: 32261972 DOI: 10.1039/c4tb01611d] [Citation(s) in RCA: 96] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Liver diseases, particularly viral hepatitis, cirrhosis and hepatocellular carcinoma, are common in clinical practice with high morbidity and mortality worldwide. Many substances for diagnostic imaging and therapy of liver diseases may have either severe adverse effects or insufficient effectiveness in vivo because of their nonspecific uptake. Therefore, by targeting the delivery of drugs into the liver or specific liver cells, drug efficiency may be largely improved. This review summarizes the up-to-date research progress focusing on nanoparticles targeting the liver for both diagnostic and therapeutic purposes. Targeting strategies, mechanisms of enhanced effects, and clinical applications of nanoparticles are discussed specifically. We believe that new targeting nanotechnology such as nanoprobes for multi-modality imaging and multifunctional nanoparticles would facilitate significant advancements in this active research area in the near future.
Collapse
Affiliation(s)
- Haolu Wang
- Therapeutics Research Centre, School of Medicine, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Jing L, Liang X, Li X, Yang Y, Dai Z. Covalent attachment of Mn-porphyrin onto doxorubicin-loaded poly(lactic acid) nanoparticles for potential magnetic resonance imaging and pH-sensitive drug delivery. Acta Biomater 2013; 9:9434-41. [PMID: 23962645 DOI: 10.1016/j.actbio.2013.08.018] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2013] [Revised: 07/31/2013] [Accepted: 08/12/2013] [Indexed: 01/30/2023]
Abstract
In this paper, theranostic nanoparticles (MnP-DOX NPs) were fabricated by conjugating Mn-porphyrin onto the surface of doxorubicin (DOX)-loaded poly(lactic acid) (PLA) nanoparticles (DOX NPs) for potential T1 magnetic resonance imaging and pH-sensitive drug delivery. An in vitro drug release study showed that the release rate of DOX from MnP-DOX NPs was slow at neutral pH but accelerated significantly in acidic conditions. It was found that MnP-DOX NPs could be easily internalized by HeLa cells and effectively suppressed the growth of HeLa cells and HT-29 cells due to the accelerated drug release in acidic lysosomal compartments. Magnetic resonance imaging (MRI) scanning analysis demonstrated that MnP-DOX NPs had much higher longitudinal relaxivity in water (r1 value of 27.8 mM(-1) s(-1) of Mn(3+)) than Mn-porphyrin (Mn(III)TPPS3NH2; r1 value of 6.70 mM(-1) s(-1) of Mn(3+)), behaving as an excellent contrast agent for T1-weighted MRI both in vitro and in vivo. In summary, such a smart and promising nanoplatform integrates multiple capabilities for effective cancer diagnosis and therapy.
Collapse
Affiliation(s)
- Lijia Jing
- School of Life Science and Technology, Harbin Institute of Technology, Harbin 150001, China
| | | | | | | | | |
Collapse
|
9
|
Liu Y, Zhang N. Gadolinium loaded nanoparticles in theranostic magnetic resonance imaging. Biomaterials 2012; 33:5363-75. [DOI: 10.1016/j.biomaterials.2012.03.084] [Citation(s) in RCA: 121] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2012] [Accepted: 03/25/2012] [Indexed: 12/15/2022]
|
10
|
Zhong J, Xiang Q, Massa LO, Qu F, Morais PC, Liu W. Second-order-like cluster-monomer transition within magnetic fluids and its impact upon the magnetic susceptibility. NANOSCALE RESEARCH LETTERS 2012; 7:167. [PMID: 22390618 PMCID: PMC3310723 DOI: 10.1186/1556-276x-7-167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/18/2011] [Accepted: 03/05/2012] [Indexed: 05/31/2023]
Abstract
The low-field (below 5 Oe) ac and dc magnetic response of a magnetic fluid [MF] sample in the range of 305 to 360 K and 410 to 455 K was experimentally and theoretically investigated. We found a systematic deviation of Curie's law, which predicts a linear temperature dependence of inverse initial susceptibility in the range of our investigation. This finding, as we hypothesized, is due to the onset of a second-order-like cluster-to-monomer transition with a critical exponent which is equal to 0.50. The susceptibility data were well fitted by a modified Langevin function, in which cluster dissociation into monomers, at the critical temperature [T*], was included. In the ac experiments, we found that T* was reducing from 381.8 to 380.4 K as the frequency of the applied field increases from 123 to 173 Hz. In addition, our ac experiments confirm that only monomers respond for the magnetic behavior of the MF sample above T*. Furthermore, our Monte Carlo simulation and analytical results support the hypothesis of a thermal-assisted dissociation of chain-like structures.PACS: 75.75.-C; 75.30.Kz; 75.30.Cr.
Collapse
Affiliation(s)
- Jing Zhong
- Department of Control Science and Engineering, Huazhong University of Science and Technology, Wuhan, 430074, China
| | - Qing Xiang
- Department of Control Science and Engineering, Huazhong University of Science and Technology, Wuhan, 430074, China
| | - Letícia O Massa
- Instituto de Física, Núcleo de Física Aplicada, Universidade de Brasília, Brasília DF, 70910-900, Brazil
| | - Fanyao Qu
- Instituto de Física, Núcleo de Física Aplicada, Universidade de Brasília, Brasília DF, 70910-900, Brazil
| | - Paulo C Morais
- Instituto de Física, Núcleo de Física Aplicada, Universidade de Brasília, Brasília DF, 70910-900, Brazil
| | - Wenzhong Liu
- Department of Control Science and Engineering, Huazhong University of Science and Technology, Wuhan, 430074, China
| |
Collapse
|
11
|
Liu Y, Chen Z, Liu C, Yu D, Lu Z, Zhang N. Gadolinium-loaded polymeric nanoparticles modified with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer. Biomaterials 2011; 32:5167-76. [PMID: 21521627 DOI: 10.1016/j.biomaterials.2011.03.077] [Citation(s) in RCA: 111] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2011] [Accepted: 03/29/2011] [Indexed: 12/21/2022]
Abstract
Molecular imaging is essential to increase the sensitivity and selectivity of cancer diagnosis especially in the early stage of tumor. Here, we designed a novel multifunctional polymeric nanoparticle contrast agent (Anti-VEGF PLA-PEG-PLL-Gd NP) simultaneously modified with Gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) and anti-vascular endothelial growth factor (VEGF) antibody to deliver Gd-DTPA to the tumor area and achieve the early diagnosis of hepatocellular carcinoma (HCC). The Anti-VEGF PLA-PEG-PLL-Gd NPs exhibited high T(1) relaxivity and no obvious cytotoxicity under the experimental concentrations in human hepatocellular carcinoma (HepG2) cells. The results of in vitro cell uptake experiments demonstrated that the uptake process of NPs was both concentration and time depended. Compared with non-targeted NPs, the Anti-VEGF antibody modified NPs showed much higher cell uptake in the HepG2 cells. During in vivo studies, the targeted NPs showed significantly signal intensity enhancement at the tumor site (mouse hepatocarcinoma tumor, H22) compared with non-targeted NPs and Gd-DTPA injection in tumor-bearing mice and the imaging time was significantly prolonged from less than an hour (Gd-DTPA injection group) to 12 h. These results demonstrated that this novel MRI contrast agent Anti-VEGF PLA-PEG-PLL-Gd NPs showed great potential in the early diagnosis of liver tumors.
Collapse
Affiliation(s)
- Yongjun Liu
- School of Pharmaceutical Science, Shandong University, Ji'nan, People's Republic of China
| | | | | | | | | | | |
Collapse
|
12
|
Enhanced gene transfection efficiency in CD13-positive vascular endothelial cells with targeted poly(lactic acid)–poly(ethylene glycol) nanoparticles through caveolae-mediated endocytosis. J Control Release 2011; 151:162-75. [DOI: 10.1016/j.jconrel.2011.02.027] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2010] [Revised: 02/24/2011] [Accepted: 02/25/2011] [Indexed: 01/06/2023]
|
13
|
Novel cationic 6-lauroxyhexyl lysinate modified poly(lactic acid)–poly(ethylene glycol) nanoparticles enhance gene transfection. J Colloid Interface Sci 2011; 354:528-35. [DOI: 10.1016/j.jcis.2010.10.062] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2010] [Revised: 10/27/2010] [Accepted: 10/28/2010] [Indexed: 01/12/2023]
|
14
|
Chen Z, Yu D, Liu C, Yang X, Zhang N, Ma C, Song J, Lu Z. Gadolinium-conjugated PLA-PEG nanoparticles as liver targeted molecular MRI contrast agent. J Drug Target 2010; 19:657-65. [DOI: 10.3109/1061186x.2010.531727] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|